<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>E-cigarette or vaping product use-associated lung injury (EVALI)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">E-cigarette or vaping product use-associated lung injury (EVALI)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">E-cigarette or vaping product use-associated lung injury (EVALI)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hasmeena Kathuria, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1352227157"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>"Vaping" is the process of inhaling an aerosol that is created by heating a liquid or wax containing various substances, such as nicotine, cannabinoids (eg, tetrahydrocannabinol, cannabidiol), flavoring, and additives (eg, glycerol, propylene glycol) [<a href="#rid1">1</a>]. Several devices are available to generate this aerosol including battery-operated electronic cigarettes (also called e-cigarettes), vape pens, or vape mods [<a href="#rid2">2</a>]. E-cigarette, or vaping, product use-associated lung injury (EVALI; originally called vaping-associated pulmonary injury), initially described in 2019, is an acute or subacute respiratory illness that can be severe and life-threatening [<a href="#rid3">3-6</a>].</p><p>The epidemiology, clinical features, evaluation, and management of EVALI will be reviewed here. The use of e-cigarettes for smoking cessation and potential health consequences of cannabis use are described separately. (See  <a class="medical medical_review" href="/z/d/html/98400.html" rel="external">"Vaping and e-cigarettes"</a> and  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p>Our approach is similar to that set out in the American Thoracic Society workshop guideline [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1568381075"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>EVALI was initially recognized in the summer of 2019 [<a href="#rid3">3,8-11</a>]. More than 2800 hospitalized cases of EVALI were reported to the Centers for Disease Control and Prevention (CDC) as of February 18, 2020, and, among those, there have been 68 deaths [<a href="#rid5">5</a>]. The CDC stopped collecting these data in February 2020; epidemiologic statistics can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Ftobacco%2Fbasic_information%2Fe-cigarettes%2Fsevere-lung-disease.html&amp;token=rQOftHru2GU4JasQu7qsKGLJ%2FDKgfKrv0lWf7kxRIyOU8lr%2B5Na9W1%2FbZH7r235i6YxmcZZariQvPZAG3CFvNwBrKQmjOJ7s5ranLjjH1cU%3D&amp;TOPIC_ID=122671" target="_blank">CDC website</a>. Approximately 66 percent of reported cases were male, and nearly 80 percent were younger than 35 years old (range 13 to 85 years) [<a href="#rid6">6</a>]. Approximately 22 percent of patients had underlying asthma [<a href="#rid3">3</a>].</p><p>Data obtained from emergency department visits associated with possible EVALI, Google searches, and case reports to the CDC confirmed similar trends in all three databases for potential cases of EVALI [<a href="#rid12">12</a>]. Peaks were seen between June and September of 2019, with a subsequent reduction in trends since then.</p><p>Sporadic cases of EVALI have been reported in Europe and in individuals traveling from the United States to Europe [<a href="#rid13">13-15</a>].</p><p class="headingAnchor" id="H2404093233"><span class="h1">PATHOGENESIS AND RISK FACTORS</span><span class="headingEndMark"> — </span>The pathogenesis of EVALI is not known. EVALI appears to be a form of acute lung injury with pathologic findings of acute fibrinous pneumonitis, diffuse alveolar damage, or organizing pneumonia, usually bronchiolocentric and accompanied by bronchiolitis [<a href="#rid16">16</a>]. EVALI may reflect a spectrum of disease processes rather than a single process. Individual reports of vaping-associated lung diseases have described acute eosinophilic pneumonia [<a href="#rid17">17</a>], diffuse alveolar hemorrhage [<a href="#rid18">18</a>], lipoid pneumonia [<a href="#rid19">19-21</a>], and respiratory-bronchiolitis interstitial lung disease, suggesting that more than one mechanism of injury may be involved. No evidence of an infectious etiology has been identified, and studies of e-cigarette fluids used by patients with EVALI have not found bacterial contamination [<a href="#rid22">22</a>].</p><p>The key risk factor for EVALI is use of an e-cigarette or similar product [<a href="#rid23">23</a>]. Examination of products used by affected patients and bronchoalveolar lavage fluid (BAL) samples has found tetrahydrocannabinol (THC) and/or vitamin E acetate in the majority [<a href="#rid3">3,6,8,16,22,24-27</a>]. However, other additives might be involved including nicotine, cannabinoid (CBD) oils, and other substances such as coconut oil and limonene [<a href="#rid22">22,24</a>]. It remains possible that other unknown additives may be responsible, and further work is needed to determine whether a causal link and specific mechanism can be established.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>THC</strong> – The majority of patients with EVALI report use of products containing THC (75 to 80 percent) [<a href="#rid3">3,6,8,26</a>]. One study compared BAL samples from 51 patients who had confirmed or probable EVALI with BAL from 99 healthy individuals from 16 states [<a href="#rid28">28</a>]; the healthy control group was comprised of asymptomatic patients who did not have EVALI, 52 of whom did not smoke or use vaping products and 47 of whom smoked cigarettes or were e-cigarette users. THC (or its metabolites) was identified in 94 percent of patients with EVALI but was undetectable in BAL from healthy individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin E acetate</strong> – Vitamin E acetate, a synthetic form of vitamin E, was initially identified in BAL samples from 29 patients with EVALI from 10 different states [<a href="#rid25">25</a>]. In a larger study of 51 patients with EVALI, vitamin E acetate was identified in 94 percent of patients compared with zero in BAL fluid from healthy individuals, one-half of whom were tobacco smokers or e-cigarette users and one-half of whom were nonusers [<a href="#rid28">28</a>]. The mechanism of vitamin E acetate toxicity is not known but may be related to byproducts of pyrolysis [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotine</strong> – Approximately 13 to 58 percent of patients with EVALI report having used nicotine-containing products with or without THC in the 90 days preceding symptom onset [<a href="#rid3">3,6,8</a>]. In a study that compared BAL fluid in patients with EVALI, nicotine or its metabolites were detected in 64 percent of patients compared with zero in healthy nonsmoking or non-vaping individuals. However, nicotine was also identified in the BAL samples of asymptomatic individuals who smoked tobacco or used e-cigarettes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other oils thought to be potential culprits (eg, CBD or other plant oils, medium-chain triglycerides, petroleum distillates, terpenes) have not been consistently found in products smoked by patients or in BAL fluid from patients with EVALI [<a href="#rid28">28</a>].</p><p></p><p>In terms of the device used for aerosolization, among 573 affected individuals, the majority used products obtained from illicit (off-the-street) or informal (eg, friends and family member) sources [<a href="#rid6">6,24</a>]. Other patients reported use of commercially available e-cigarette products (ie, bottles, cartridges, or pods) and also addition of homemade liquids to previously used cartridges or pods. While most used aerosolized products, some dripped the substance onto the heating element (called "dripping") and others used highly concentrated nicotine or THC prepared in a waxlike substance and smoked in a pipe (called "dabbing"). It is also possible that the process of mixing and heating active and inactive components could lead to production of toxic new agents [<a href="#rid22">22</a>].</p><p>Whether underlying comorbidities increase the risk is unclear, but one study reported that 68 percent had at least one comorbidity [<a href="#rid2">2</a>].</p><p>An animal model of EVALI has been described and may shed light on the pathogenesis of this disease [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H4113759245"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Information about the clinical presentation of EVALI is largely derived from a case series of 98 patients who met a case definition for EVALI  (<a class="graphic graphic_table graphicRef122905" href="/z/d/graphic/122905.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. A similar pattern of symptoms is reported in other series, including adolescents [<a href="#rid2">2,11,23,26,31-35</a>].</p><p>The median patient age was 21; 78 percent were males, and 68 percent had at least one comorbidity. No patients died during the initial hospital admission.</p><p>Respiratory symptoms included shortness of breath (85 percent), cough (85 percent), chest pain (52 percent), pleuritic chest pain (36 percent), and hemoptysis (8 percent) [<a href="#rid3">3</a>]. Constitutional symptoms of subjective fever and chills were reported by 84 and 60 percent, respectively.</p><p>Gastrointestinal symptoms were common (77 percent) and included nausea (66 percent), vomiting (61 percent), diarrhea (44 percent), and abdominal pain (34 percent) [<a href="#rid3">3</a>]. Rarely, gastrointestinal symptoms predominate [<a href="#rid36">36</a>], as in one teenage boy with presumed EVALI who reported nausea, vomiting, weight loss, and fever but denied respiratory symptoms despite imaging findings consistent with EVALI [<a href="#rid37">37</a>].</p><p>On physical examination, fever was present in 33 percent, tachycardia in 63 percent, and tachypnea in 43 percent [<a href="#rid3">3</a>]. Approximately 58 percent were hypoxemic, with a pulse oxygen saturation ≤88 percent in 25 percent.</p><p>Progression to respiratory failure is common. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H4012230653"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>EVALI should be suspected in patients who have a history of vaping or other use of e-cigarette-related products and have a pneumonia-like syndrome, progressive dyspnea, and/or worsening hypoxemia (see <a class="local">'Clinical features'</a> above). Useful questions include the following  (<a class="graphic graphic_table graphicRef122907" href="/z/d/graphic/122907.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>What type(s) of vaping device were used (eg, bottle, cartridge, pod)?</p><p class="bulletIndent1"><span class="glyph">●</span>What products (eg, nicotine, tetrahydrocannabinol [THC], cannabidiol, flavored liquid) were vaped?</p><p class="bulletIndent1"><span class="glyph">●</span>Were cartridges or pods reused? If so, were they filled with homemade, unlicensed, or commercially licensed products?</p><p class="bulletIndent1"><span class="glyph">●</span>Was the product concentrated prior to use (eg, dabbing)?</p><p class="bulletIndent1"><span class="glyph">●</span>When did the patient start vaping relative to the onset of symptoms?</p><p class="bulletIndent1"><span class="glyph">●</span>How often was the patient vaping (eg, number of cartridges or pods per day, frequency of puffs)? Did they Valsalva at end-inhalation (thought to increase the rate of absorption)?</p><p class="bulletIndent1"><span class="glyph">●</span>Were they also smoking tobacco?</p><p></p><p>The specific steps in the evaluation depend on the acuity of illness, other exposures (eg, influenza, coronavirus disease 2019 [COVID-19], coccidioidomycosis, travel, medications known to cause lung toxicity, occupations or other activities associated with hypersensitivity pneumonitis), evidence of underlying disease (eg, heart failure, rheumatic disease, immunodeficiency), and presence of opacities on imaging.</p><p class="headingAnchor" id="H2632975441"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>The laboratory evaluation of suspected EVALI is designed to exclude processes in the differential diagnosis, most importantly, community-acquired pneumonia, COVID-19 pneumonia, and also acute eosinophilic pneumonia. We typically obtain complete blood count and differential, blood urea nitrogen, and creatinine. Gastrointestinal symptoms might prompt liver function tests. Microbiologic testing is based on the severity of respiratory impairment and site of care. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Microbiologic testing'</a> and  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p>While there is general interest in using biomarkers such as C-reactive protein and procalcitonin to discriminate bacterial infection from other causes of pneumonitis, these studies are not routinely obtained. A single-center study of 24 patients with EVALI related to THC noted elevated markers of coagulation (eg, international normalized ratio) and inflammation (C-reactive protein, erythrocyte sedimentation rate, procalcitonin), although the significance is uncertain [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Laboratory evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections"</a>.)</p><p class="headingAnchor" id="H3991114767"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>The majority of patients (83 percent) presenting with suspected EVALI have a chest radiograph that shows diffuse hazy or consolidative opacities [<a href="#rid3">3,34,40</a>]. For those with progressive dyspnea or hypoxemia, the next step is often computed tomography pulmonary angiography (CTPA) to exclude pulmonary embolism or high-resolution CT (HRCT) in those without risk factors for pulmonary embolism. (See  <a class="medical medical_review" href="/z/d/html/292.html" rel="external">"Approach to the adult with dyspnea in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p>Bilateral opacities are typical in EVALI [<a href="#rid34">34,41-45</a>]. In a series of 98 patients, bilateral opacities were noted in 100 percent, either on the chest radiograph or chest CT [<a href="#rid3">3</a>]. The CT opacities were typically ground glass in density and sometimes spared the subpleural space. Pleural effusions were less common (approximately 10 percent). These features are consistent with diffuse alveolar damage, as is seen in acute respiratory distress syndrome. (See  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults", section on 'Imaging'</a>.)</p><p>A separate series confirmed bilaterality and also noted basilar predominance of consolidative and ground glass opacities [<a href="#rid41">41</a>].</p><p>Spontaneous pneumothorax and pneumomediastinum associated with vaping has been described [<a href="#rid46">46,47</a>].</p><p>In addition, a variety of radiographic patterns have been noted with features suggestive of one or more of the following processes [<a href="#rid41">41,42,48</a>] (see <a class="local">'Differential diagnosis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse alveolar damage – Dependent consolidation, diffuse ground glass, air bronchograms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute eosinophilic pneumonia – Nodular areas of consolidation, diffuse ground glass, septal thickening, small amount of pleural fluid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity pneumonitis – Centrilobular ground glass opacities anteriorly and more confluent ground glass opacities in dependent areas, and lobules of mosaic attenuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organizing pneumonia – Diffuse, multifocal discrete and confluent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipoid pneumonia – Ground glass and consolidative opacities in the dependent portions of the lungs, with areas of fat attenuation (&lt;-30 Hounsfield units) are characteristic features of lipoid pneumonia, but areas of fat attenuation are typically absent in EVALI even when bronchoalveolar lavage (BAL) fluid has a high number of lipid-laden macrophages [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H1724252381"><span class="h2">Flexible bronchoscopy and bronchoalveolar lavage</span><span class="headingEndMark"> — </span>Flexible bronchoscopy with BAL can be helpful in excluding other causes of nonresolving or progressive pneumonitis (eg, infection and acute eosinophilic pneumonia) and is generally performed in patients with progressive or severe symptoms. Samples of BAL fluid should be sent for cell counts, cytopathology, and studies to exclude bacterial, mycobacterial, fungal, and viral pathogens. (See  <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a> and  <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">"Nonresolving pneumonia", section on 'Bronchoscopy'</a>.)</p><p>Reported cell counts in EVALI are variable but tend to show an increase in neutrophils (58 percent, with a range 10 to 91 percent), although eosinophils have been reported in isolated cases [<a href="#rid3">3,17</a>]. Identification of lipid laden-macrophages (eg, positive Oil-red-O stain) is a common but nonspecific finding [<a href="#rid3">3,31,34,49-51</a>].</p><p class="headingAnchor" id="H1493448180"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Only a few patients with EVALI have undergone lung biopsy or autopsy, so a full description of the range of histopathologic features awaits further study. Reported findings are consistent with acute lung injury and include features such as acute fibrinous pneumonitis, diffuse alveolar damage, foamy (lipid-laden) macrophages (seen in all cases), and organizing pneumonia (usually bronchiolocentric and accompanied by bronchiolitis) [<a href="#rid3">3,4,16,49,52,53</a>]. Peribronchiolar granulomas (with negative testing for infectious pathogens) were noted in one series [<a href="#rid3">3</a>] but not in a larger series [<a href="#rid16">16</a>]. Neutrophils are often prominently present; eosinophils are rare [<a href="#rid16">16</a>]. One autopsy report described type 2 pneumocyte hyperplasia and scattered atypical mitotic figures [<a href="#rid54">54</a>]. Whether features represent various stages of lung injury is unknown.</p><p>Individual case reports have described multinucleated giant cells that suggested a foreign body reaction to lipophilic material [<a href="#rid41">41,55</a>]. In addition, one case of diffuse alveolar hemorrhage has been reported [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H862560329"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Formal diagnostic criteria for EVALI have not been agreed upon, and the heterogeneous presentations suggest that EVALI comprises several different forms of lung injury. EVALI is a diagnosis of exclusion and requires particular attention to the exclusion of lung infection and other causes of progressive respiratory insufficiency. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Criteria used as a case definition for EVALI provide a reasonable foundation for a "probable case" or a "confirmed case"  (<a class="graphic graphic_table graphicRef122905" href="/z/d/graphic/122905.html" rel="external">table 1</a>) [<a href="#rid3">3,8</a>]. Criteria for a confirmed case include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of an e-cigarette or related product (eg, "vaping" or "dabbing") in the previous 90 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung opacities on chest radiograph or computed tomography. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of lung infection based on negative influenza polymerase chain reaction or rapid test (unless out of season), viral respiratory panel, and, as clinically indicated, urine antigen tests for <em>Legionella</em> and <em>Streptococcus pneumoniae</em>, blood cultures, sputum culture (if producing sputum), bronchoalveolar lavage (if performed), and testing for human immunodeficiency virus (HIV)-related opportunistic infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of a likely alternative diagnosis (eg, cardiac, neoplastic, rheumatologic). (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p>Similar criteria, but without conclusive exclusion of infection, are used for a probable diagnosis of EVALI  (<a class="graphic graphic_table graphicRef122905" href="/z/d/graphic/122905.html" rel="external">table 1</a>).</p><p>It is important to note that criteria used for a case definition were developed prior to the COVID-19 pandemic [<a href="#rid56">56</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdph.ca.gov%2FPrograms%2FCCDPHP%2FPublishingImages%2FPages%2FVaping-Health-Advisory%2FCDPH+Advisory+EVALI+Case+Definition+Update_May+9%2C+2020.pdf%23search%3Devali%2520cahan&amp;token=yhjtC5XVMGXQHY3EAierkUNmcwgLT1kBghjue2UxsXehyjtylfCmqVeYW9xisSbpZHA6V89UIarDmUZbIv4wPCynsqf1OLF9EGQfwtwx3KkUc07EkqgruEBd9nikh0dy7m7sKCIGuUKMyNwuk%2FhUCOx7AStnb5jYvi%2FkSbJafbdgawk9LgqNIFcnNxs7KEFRiln0OvDd2CzUN2zkq%2BFB5A%3D%3D&amp;TOPIC_ID=122671" target="_blank">California Department of Public Health</a> has provisionally changed the definition of a confirmed EVALI case to require a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test. We encourage clinicians to be familiar with their <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpublichealthgateway%2Fhealthdirectories%2Fhealthdepartments.html&amp;token=Bi7tDwXcUQ4STL1BoFuqpd2B4S1mvrzPmU4jdBftdOChftnb3cgiIl%2BEOpIeXEvJMUujoqmdbfJBRrcDu4k3LU9MYg7VdOgsJrk4i5Fy1P4%3D&amp;TOPIC_ID=122671" target="_blank">state health departments</a> information on diagnostic requirements.</p><p class="headingAnchor" id="H1630590648"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of respiratory diseases are in the differential diagnosis of EVALI. All patients with suspected EVALI should undergo an evaluation for community-acquired pneumonia and COVID-19, which are much more common. Other processes that are listed here have occasionally been described in association with vaping but did not figure prominently in the cluster of cases of EVALI reported in 2019 [<a href="#rid3">3,16</a>]. Thus, they are considered in the differential diagnosis, rather than as manifestations of EVALI.</p><p>Chest CT may provide clues to the presence of these disorders but is generally not diagnostic. Bronchoscopy with bronchoalveolar lavage (BAL) and, sometimes, lung biopsy may be needed when a definitive diagnosis is needed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community-acquired pneumonia (CAP)</strong> – It is important to exclude CAP when evaluating a patient with suspected EVALI as prompt and directed antimicrobial treatment is essential to successful treatment. The presentation of CAP overlaps with EVALI and ranges from mild pneumonia with fever and productive cough to severe pneumonia with acute respiratory distress syndrome and sepsis. Like EVALI, gastrointestinal symptoms are common among patients with CAP.</p><p></p><p class="bulletIndent1">The selection of microbiologic tests and initiation of empiric antibiotic therapy for CAP depends on the severity of illness, risk factors for resistant or atypical pathogens, comorbidities, and local patterns of antibiotic resistance. The presentation, evaluation and management of CAP are described separately. (See  <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – COVID-19, a cause of CAP, has clinical features similar to EVALI, such as cough, dyspnea, fever, and diarrhea [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute eosinophilic pneumonia (AEP)</strong> – AEP has a similar time course of symptom onset and is typically associated with BAL eosinophilia (&gt;25 percent eosinophils) and has been reported in association with vaping and use of heat-not-burn cigarettes, as well as a number of other potential irritants and toxins (see  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Etiology'</a>). However, BAL eosinophilia was not reported in a series of 98 patients with EVALI of whom 26 underwent BAL [<a href="#rid3">3</a>], nor in a separate report of six patients with EVALI [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organizing pneumonia</strong> – Organizing pneumonia, a diffuse interstitial lung disease (ILD) that affects the distal bronchioles, respiratory bronchioles, alveolar duct, and alveolar walls, has been reported in a few patients after use of e-cigarettes [<a href="#rid58">58,59</a>]. In one patient, dyspnea, chest pain, and hypoxemia developed after using e-cigarettes for a month as part of a smoking cessation program and progressed to acute respiratory failure [<a href="#rid58">58</a>]. Organizing pneumonia was diagnosed by surgical lung biopsy after less invasive studies were negative. Improvement followed systemic glucocorticoids and e-cigarette abstinence. The evaluation and management of organizing pneumonia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoid pneumonia</strong> – Lipoid pneumonia is most commonly reported after aspiration of ingested <a class="drug drug_general" data-topicid="10213" href="/z/d/drug information/10213.html" rel="external">mineral oil</a> [<a href="#rid60">60</a>] but has also been reported after vaping with products containing vegetable oil [<a href="#rid19">19-21,61</a>]. High-resolution CT findings of lipoid pneumonia typically include consolidative and ground glass opacities, a crazy paving pattern, interlobular septal thickening, and nodular or mass-like consolidation [<a href="#rid62">62</a>]. Areas with negative attenuation (eg, -17 to -114; similar to nearby adipose tissue) are seen in approximately one-half to two-thirds of patients with mineral oil-associated lipoid pneumonia [<a href="#rid60">60</a>]. However, areas of negative attenuation have not been reported with EVALI, even among patients with lipid-laden macrophages in the bronchoalveolar lavage fluid [<a href="#rid31">31</a>]. (See <a class="local">'Flexible bronchoscopy and bronchoalveolar lavage'</a> above and  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults", section on 'Lipoid pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse alveolar hemorrhage (DAH)</strong> – DAH is in the differential diagnosis of EVALI and is a reported consequence of EVALI. As an example, one patient developed dyspnea, hemoptysis, and hypoxemia after approximately one month of frequent vaping with a variety of flavored vaping solutions [<a href="#rid18">18</a>]. CT revealed patchy areas of consolidation; sequential bronchoalveolar lavage revealed progressively more hemorrhagic returns, and a surgical lung biopsy confirmed alveolar hemorrhage with capillaritis and diffuse alveolar damage. Treatment with pulse dose steroids led to complete radiographic clearing over two weeks. A separate report described onset of DAH in a patient who vaped large volumes of cinnamon-flavored nicotine solution daily; vaping cessation led to resolution [<a href="#rid63">63</a>]. The evaluation of DAH is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis (HP)</strong> – The possibility that vaping can cause HP has been raised, although supportive information is limited [<a href="#rid41">41,64-66</a>]. HP would be in the differential diagnosis of upper lung zone opacities and centrilobular nodules that are seen in some cases of EVALI. The clinical features and diagnosis of HP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory bronchiolitis ILD (RBILD)</strong> – RBILD is generally associated with chronic inhalation of tobacco smoke. A single patient has been reported in association with vaping nicotine. While the patient was continuing to smoke cigarettes, the appearance and resolution of symptoms and radiographic evidence of RBILD temporally followed onset and cessation of vaping [<a href="#rid67">67</a>]. CT features of RBILD include diffuse or patchy ground glass opacities, centrilobular nodules, bronchial wall thickening, and air trapping. The evaluation and diagnosis of RBILD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">"Respiratory bronchiolitis-associated interstitial lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Giant cell pneumonitis</strong> – Giant cell pneumonitis, typically associated with heavy metal exposure, was described in a single patient with progressive ILD over a six-month period of vaping [<a href="#rid41">41</a>]. CT demonstrated peripheral reticulation, ground glass opacities, and mild traction bronchiectasis that developed. Lung biopsy revealed giant cell pneumonitis that was believed to be due to cobalt exposure from the vape pen used by the patient [<a href="#rid41">41</a>]. Cobalt-related ILD is associated with multinucleated giant cells on histopathology; other ILD patterns, such as usual interstitial pneumonia, desquamative interstitial pneumonia, or hypersensitivity pneumonia, can also be present [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a>.)</p><p></p><p class="headingAnchor" id="H2971387458"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The optimal treatment of EVALI is not known. The most important step is to ensure that community-acquired pneumonia (CAP), including COVID-19, is not overlooked or undertreated, as infectious pneumonias are much more common than EVALI. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>Hospitalization is advisable for any patient with suspected EVALI who has respiratory distress, decreased oxygen saturation (eg, &lt;95 percent on room air), significant comorbidity that compromises lung reserve, and/or suboptimal access to follow-up within 24 to 48 hours [<a href="#rid69">69</a>]. Patients not admitted to the hospital should be advised of the risk of rapid deterioration and instructed to completely avoid vaping and to seek medical care if they experience worsening symptoms.</p><p class="headingAnchor" id="H1145081944"><span class="h2">Empiric antibiotics</span><span class="headingEndMark"> — </span>For the majority of patients with EVALI, empiric antibiotics are initiated to cover likely pathogens of CAP, pending the results of the initial evaluation and response to therapy. Antiviral therapy (eg, COVID-19, influenza) may also be appropriate. (See  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="headingAnchor" id="H3742804953"><span class="h2">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids have been used in the majority of patients with EVALI [<a href="#rid3">3,21,31,70</a>], but the efficacy has not been formally studied. As EVALI appears to reflect a spectrum of responses to lung injury, it is possible that the various presentations of EVALI will respond differently to glucocorticoids.</p><p>The decision regarding initiation of glucocorticoid therapy is challenging and requires individualized assessment [<a href="#rid2">2,3,16</a>]. We do not advise routine use of glucocorticoids, because the efficacy in EVALI is unknown. However, given the potentially life-threatening nature of EVALI, we suggest initiation of systemic glucocorticoids for patients who meet criteria for EVALI and have progressively worsening symptoms and/or hypoxemia. For patients with less severe presentations, it is reasonable to withhold initiation of glucocorticoids because of the greater likelihood of an infectious cause in patients with fever, dyspnea, and chest pain; the potential adverse effects of glucocorticoids; and the potential for resolution with supportive care.</p><p>As exceptions, patients with imaging, bronchoalveolar lavage, or biopsy evidence of acute eosinophilic pneumonia or cryptogenic organizing pneumonia should be treated with systemic glucocorticoids according to the usual management of those processes. (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p>If the decision is made to administer glucocorticoids for EVALI, we favor a short course, starting with the equivalent of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 0.5 to 1 mg/kg per day and tapering over 5 to 10 days, guided by the clinical course [<a href="#rid2">2,3,21,31</a>]. Commonly prescribed glucocorticoid regimens consist of 40 to 60 mg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> ranging from three days up to two weeks [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Glucocorticoids'</a>.)</p><p>The evidence regarding the benefit of systemic glucocorticoids is observational. In a large case series of 98 patients, 78 (84 percent) received systemic glucocorticoids (81 percent intravenously) and the treating clinicians attributed clinical improvement to the glucocorticoids [<a href="#rid3">3</a>]. In a detailed analysis of five of these patients, extubation from mechanical ventilation occurred 5 to 10 days after initiation of treatment with glucocorticoids. The exact dose of glucocorticoids was not provided, but the duration of therapy among the 46 treated patients was ≥7 days.</p><p>In a report of five patients, intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 120 to 500 mg was administered daily; all five patients survived (one required mechanical ventilation, three required intensive care unit admission) [<a href="#rid21">21</a>]. Clinical improvement was noted by 24 to 72 hours after initiation of methylprednisolone.</p><p>In a separate series of six patients, one patient developed progressive respiratory failure despite <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 mg/kg) and required extracorporeal membrane oxygenation (ECMO), although the relative timing of treatment initiation and worsening of hypoxemia was not provided [<a href="#rid31">31</a>]. In the same series, two of six patients whose hypoxemia was managed with oxygen by nasal cannula did not receive systemic glucocorticoids and improved spontaneously and one patient had progressive respiratory insufficiency despite glucocorticoids, so this therapy was stopped, and the patient improved with supportive care.</p><p class="headingAnchor" id="H4159089888"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Approximately 95 percent of patients with EVALI have required hospitalization [<a href="#rid10">10</a>]. Supportive care initially focuses on supplemental oxygen with a target pulse oxygen saturation of 88 to 92 percent. If nasal cannula are insufficient to achieve this target, high-flow oxygen can be provided through a face mask or, possibly, high-flow nasal cannula (HFNC). If hypoxemia worsens, management follows that for acute respiratory distress syndrome. In the largest series, mechanical ventilation was required in approximately 26 percent of patients; rarely, ECMO has been needed [<a href="#rid3">3,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a> and <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2127264762"><span class="h2">Discharge and follow-up</span><span class="headingEndMark"> — </span>Based on concerns about recurrent disease, it is prudent to ensure that vital signs, oxygenation, and exercise tolerance are stable for 24 to 48 hours prior to discharge after hospitalization for EVALI [<a href="#rid71">71</a>]. In addition, symptoms should have resolved and comorbid conditions that may have been exacerbated by EVALI reassessed. Follow-up examination should be scheduled within 48 hours of discharge or sooner if the patient's condition deteriorates. This advice is based on a report that 13 of 1139 patients discharged after an episode of EVALI (2.7 percent) required rehospitalization and seven patients died [<a href="#rid71">71</a>]. Patients who died or required rehospitalization were typically older and had one or more underlying chronic condition. All of those who died after discharge had required mechanical ventilation. Rehospitalization typically occurred at a median of four days after discharge and death at a median of three days.</p><p>Few studies have reported follow-up data. We suggest follow-up evaluation clinically and radiologically to ensure resolution of the process is appropriate. In one study of 31 patients, the majority had improved symptoms at two weeks, although two-thirds had some residual symptoms [<a href="#rid34">34</a>]. Follow-up chest radiographs in 10 showed complete or near-complete resolution of abnormalities, while pulmonary function tests showed a mild reduction in diffusing capacity. Follow-up for long-term sequelae of mechanical ventilation or critical illness is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88330.html" rel="external">"Post-intensive care syndrome (PICS) in adults: Clinical features and diagnostic evaluation"</a>.)</p><p>If glucocorticoids have been used to treat EVALI, they should be tapered as quickly as possible (eg, over 5 to 10 days) and discontinued.</p><p>Until the exact mechanism of EVALI is known, it is reasonable to advise patients with EVALI to completely avoid vaping in the future.</p><p class="headingAnchor" id="H2238037790"><span class="h1">COMMUNICATION WITH HEALTH DEPARTMENT</span><span class="headingEndMark"> — </span>The Centers for Disease Control and Prevention (CDC) encourages reporting of hospitalized patients with possible EVALI to local or state health departments and provides links to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpublichealthgateway%2Fhealthdirectories%2Fhealthdepartments.html&amp;token=Bi7tDwXcUQ4STL1BoFuqpd2B4S1mvrzPmU4jdBftdOChftnb3cgiIl%2BEOpIeXEvJMUujoqmdbfJBRrcDu4k3LU9MYg7VdOgsJrk4i5Fy1P4%3D&amp;TOPIC_ID=122671" target="_blank">state health departments</a> for information on reporting requirements [<a href="#rid72">72</a>]. Additionally, the CDC suggests that clinical details about the patient's vaping practices be obtained and recorded  (<a class="graphic graphic_table graphicRef122907" href="/z/d/graphic/122907.html" rel="external">table 2</a>) [<a href="#rid73">73</a>]. (See <a class="local">'Evaluation'</a> above.)</p><p>Residual samples of the vaping product used by the patient may help to determine the causative substance, but this is not always necessary. Testing can be coordinated with the local or state health department and/or the US Food and Drug Administration [<a href="#rid72">72,74</a>].</p><p class="headingAnchor" id="H1910954281"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>EVALI is a serious respiratory illness [<a href="#rid3">3,8-10</a>]. As of February 18, 2020, over 2800 patients have been hospitalized with EVALI in the United States and, among those, 68 have died [<a href="#rid5">5</a>]. Among 1604 patients admitted to the intensive care unit, 36 percent required intubation and mechanical ventilation and 7 percent required extracorporeal membrane oxygenation (ECMO); most patients (93 percent) survived to discharge [<a href="#rid70">70</a>]. Updated epidemiologic statistics can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Ftobacco%2Fbasic_information%2Fe-cigarettes%2Fsevere-lung-disease.html&amp;token=rQOftHru2GU4JasQu7qsKGLJ%2FDKgfKrv0lWf7kxRIyOU8lr%2B5Na9W1%2FbZH7r235i6YxmcZZariQvPZAG3CFvNwBrKQmjOJ7s5ranLjjH1cU%3D&amp;TOPIC_ID=122671" target="_blank">Centers for Disease Control and Prevention website</a>.</p><p>When comparing fatal and nonfatal cases of EVALI, the proportion of fatal cases was higher among patients over age 35 years and (when the medical history was available) among those with a history of asthma (23 versus 8 percent), cardiac disease (47 versus 10 percent), or a mental health condition (65 versus 41 percent) [<a href="#rid75">75</a>]. Among patients who died, 52 percent were obese.</p><p>Data describing long term outcomes suggest significant morbidity [<a href="#rid2">2,76-78</a>]. A retrospective review assessed one-year outcomes of 41 patients diagnosed with confirmed or probable EVALI [<a href="#rid2">2</a>]. Ten (24 percent) patients had at least one emergency department visit and 10 (24 percent) patients had at least one readmission within a year of initial hospital admission. Six (60 percent) of the readmissions were due to respiratory diagnoses (persistent or recurrent EVALI, asthma, or bacterial pneumonia). During follow-up, 13 (45 percent) remained symptomatic at the first outpatient visit, but nine became asymptomatic within the first year. Nine patients had abnormal pulmonary function tests (restriction, obstruction, mixed, or abnormal diffusion) [<a href="#rid2">2</a>]. In six patients who had repeat pulmonary function testing within one year after initial admission, abnormalities in pulmonary function testing had resolved. Other case series among adolescents suggest residual lung dysfunction, mainly diffusion abnormalities in the short term (&lt;2 months post-discharge) but do not provide long-term data [<a href="#rid76">76,77</a>]. Of 33 patients with a documented subsequent health care encounter after hospitalization for EVALI, 16 (48 percent) patients had stopped vaping, 4 (12 percent) reported continued use of e-cigarettes, and 13 (39 percent) patients did not have a vaping assessment recorded [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2491899020"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Until more is known about the specific cause(s) of EVALI, the Centers for Disease Control and Prevention advise complete avoidance of tetrahydrocannabinol-containing e-cigarettes or vaping products [<a href="#rid8">8</a>]. Furthermore, they advise avoidance of all e-cigarette or vaping products by youths, young adults, pregnant women, and adults who do not currently use tobacco products.</p><p>For those who wish to continue use of tobacco-containing e-cigarette products to help with tobacco smoking cessation, it appears safer to purchase commercially prepared products, rather than purchasing unlicensed products, although legally purchased products may contain potentially harmful substances.</p><p class="headingAnchor" id="H4262696407"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">"Society guideline links: Pediatric pneumonia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/130958.html" rel="external">"Society guideline links: COVID-19 – General guidelines for diagnostic testing"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/130968.html" rel="external">"Society guideline links: COVID-19 – Pediatrics"</a>.)</p><p class="headingAnchor" id="H3095889743"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – E-cigarette, or vaping, product use-associated lung injury (EVALI) is an acute or subacute respiratory illness that can be severe and life-threatening. Vaping is the process of inhaling an aerosol created by heating a substance such as nicotine or tetrahydrocannabinol (THC) with a battery-operated electronic device such as an electronic cigarette (e-cigarette). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – More than 2000 cases have been reported; approximately two-thirds are male, and approximately 80 percent are under 35 years old (range 13 to 75 years). The incidence has declined since the original outbreak in the summer of 2019. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The exact pathogenesis of EVALI is unknown. The various presentations of EVALI suggest acute lung injury, possibly reflecting a spectrum of disease processes rather than a single process. No evidence of an infectious etiology has been identified. (See <a class="local">'Pathogenesis and risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The key risk factor for EVALI is use of an e-cigarette or similar product; no single constituent has been identified that is common to all cases. Potential candidate toxins include THC and vitamin E acetate, although other compounds including nicotine and other unknown additives have been implicated. (See <a class="local">'Pathogenesis and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The mean duration of symptoms prior to presentation is six days with a range of zero days to two months. Respiratory symptoms include dyspnea, cough, chest pain (sometimes pleuritic), and hemoptysis. Approximately one-third of patients may progress to acute respiratory failure requiring mechanical ventilation. Subjective fever is reported by 85 percent; gastrointestinal symptoms are also common and include nausea, vomiting, diarrhea, and abdominal pain. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Criteria used as a case definition provide a reasonable foundation for a clinical diagnosis as formal diagnostic criteria for EVALI have not been agreed upon  (<a class="graphic graphic_table graphicRef122905" href="/z/d/graphic/122905.html" rel="external">table 1</a>); a negative nucleic acid test for SARS-CoV-2 should also be included. The case definition criteria include the following (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of an e-cigarette or related product in the previous 90 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lung opacities on chest radiograph or CT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of lung infection based on negative influenza polymerase chain reaction or rapid test (unless out of season), viral respiratory panel, and, as clinically indicated, urine antigen tests for <em>Legionella</em> and <em>Streptococcus pneumoniae</em>, blood cultures, sputum culture (if producing sputum), bronchoalveolar lavage (if performed), and testing for HIV-related opportunistic infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of a likely alternative diagnosis (eg, cardiac, neoplastic, rheumatologic).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – A variety of respiratory diseases are in the differential diagnosis of EVALI. Community-acquired pneumonia (including COVID-19) should be carefully evaluated. Other processes, such as acute eosinophilic pneumonia, organizing pneumonia, lipoid pneumonia, and diffuse alveolar hemorrhage have occasionally been described in association with e-cigarette product use but either did not figure prominently in the reported cases of EVALI or have some unique features. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The optimal treatment of EVALI is not known. However, the following are appropriate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antibiotics</strong> – For the majority of patients with EVALI, empiric antibiotics are initiated to cover likely pathogens, pending the results of the initial evaluation and response to therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selective use of glucocorticoids</strong> – The efficacy of systemic glucocorticoids is unknown, and we do not advise routine use in EVALI. However, for patients who meet criteria for EVALI and have progressively worsening symptoms and hypoxemia, we suggest initiation of systemic glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pending further data, it is reasonable to use an initial dose of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (or equivalent) 0.5 to 1 mg/kg per day and taper over 5 to 10 days. (See <a class="local">'Systemic glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Supportive care focuses on oxygenation and, when indicated, noninvasive or invasive ventilation. (See <a class="local">'Supportive care'</a> above and  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should be followed clinically and radiologically until the point of resolution. (See <a class="local">'Discharge and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis is variable, with many cases resolving completely, while a small number progress to death. Risk factors for disease progression and death are unknown. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resources</strong> – In many states, EVALI cases are being collected and reviewed. The Centers for Disease Control and Prevention (CDC) has links to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpublichealthgateway%2Fhealthdirectories%2Fhealthdepartments.html&amp;token=Bi7tDwXcUQ4STL1BoFuqpd2B4S1mvrzPmU4jdBftdOChftnb3cgiIl%2BEOpIeXEvJMUujoqmdbfJBRrcDu4k3LU9MYg7VdOgsJrk4i5Fy1P4%3D&amp;TOPIC_ID=122671" target="_blank">state health departments</a> for information on reporting requirements. (See <a class="local">'Communication with health department'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Until more is known about the specific cause(s) of EVALI, the CDC advises complete avoidance of THC-containing e-cigarettes or vaping products and avoidance of all e-cigarette or vaping products by youths, young adults, pregnant women, and adults who do not currently use tobacco products. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019; 366:l5275.</a></li><li><a class="nounderline abstract_t">Triantafyllou GA, Tiberio PJ, Zou RH, et al. Vaping-associated Acute Lung Injury: A Case Series. Am J Respir Crit Care Med 2019; 200:1430.</a></li><li><a class="nounderline abstract_t">Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N Engl J Med 2020; 382:903.</a></li><li><a class="nounderline abstract_t">Kligerman S, Raptis C, Larsen B, et al. Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions. Radiology 2020; 294:491.</a></li><li class="breakAll">Centers for Disease Control and Prevention (CDC). Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. Available at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#latest-information (Accessed on December 06, 2021).</li><li class="breakAll">Centers for Disease Control and Prevention. Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. Available at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Rebuli ME, Rose JJ, Noël A, et al. The E-cigarette or Vaping Product Use-Associated Lung Injury Epidemic: Pathogenesis, Management, and Future Directions: An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 2023; 20:1.</a></li><li><a class="nounderline abstract_t">Schier JG, Meiman JG, Layden J, et al. Severe Pulmonary Disease Associated with Electronic-Cigarette-Product Use - Interim Guidance. MMWR Morb Mortal Wkly Rep 2019; 68:787.</a></li><li><a class="nounderline abstract_t">Hswen Y, Brownstein JS. Real-Time Digital Surveillance of Vaping-Induced Pulmonary Disease. N Engl J Med 2019; 381:1778.</a></li><li><a class="nounderline abstract_t">Chatham-Stephens K, Roguski K, Jang Y, et al. Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019. MMWR Morb Mortal Wkly Rep 2019; 68:1076.</a></li><li><a class="nounderline abstract_t">Jonas AM, Raj R. Vaping-Related Acute Parenchymal Lung Injury: A Systematic Review. Chest 2020; 158:1555.</a></li><li><a class="nounderline abstract_t">Hartnett KP, Kite-Powell A, Patel MT, et al. Syndromic Surveillance for E-Cigarette, or Vaping, Product Use-Associated Lung Injury. N Engl J Med 2020; 382:766.</a></li><li><a class="nounderline abstract_t">Casanova GS, Amaro R, Soler N, et al. An imported case of e-cigarette or vaping associated lung injury in Barcelona. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Villeneuve T, Prevot G, Le Borgne A, et al. Diffuse alveolar haemorrhage secondary to e-cigarette "vaping" associated lung injury (EVALI) in a young European consumer. Eur Respir J 2020; 56.</a></li><li><a class="nounderline abstract_t">Marlière C, De Greef J, Gohy S, et al. Fatal e-cigarette or vaping associated lung injury (EVALI): a first case report in Europe. Eur Respir J 2020; 56.</a></li><li><a class="nounderline abstract_t">Butt YM, Smith ML, Tazelaar HD, et al. Pathology of Vaping-Associated Lung Injury. N Engl J Med 2019; 381:1780.</a></li><li><a class="nounderline abstract_t">Thota D, Latham E. Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor. J Emerg Med 2014; 47:15.</a></li><li><a class="nounderline abstract_t">Agustin M, Yamamoto M, Cabrera F, Eusebio R. Diffuse Alveolar Hemorrhage Induced by Vaping. Case Rep Pulmonol 2018; 2018:9724530.</a></li><li><a class="nounderline abstract_t">Viswam D, Trotter S, Burge PS, Walters GI. Respiratory failure caused by lipoid pneumonia from vaping e-cigarettes. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">McCauley L, Markin C, Hosmer D. An unexpected consequence of electronic cigarette use. Chest 2012; 141:1110.</a></li><li><a class="nounderline abstract_t">Davidson K, Brancato A, Heetderks P, et al. Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia - North Carolina, July-August 2019. MMWR Morb Mortal Wkly Rep 2019; 68:784.</a></li><li><a class="nounderline abstract_t">Christiani DC. Vaping-Induced Acute Lung Injury. N Engl J Med 2020; 382:960.</a></li><li><a class="nounderline abstract_t">Perrine CG, Pickens CM, Boehmer TK, et al. Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019. MMWR Morb Mortal Wkly Rep 2019; 68:860.</a></li><li><a class="nounderline abstract_t">Ghinai I, Pray IW, Navon L, et al. E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury - Illinois and Wisconsin, April-September 2019. MMWR Morb Mortal Wkly Rep 2019; 68:865.</a></li><li><a class="nounderline abstract_t">Blount BC, Karwowski MP, Morel-Espinosa M, et al. Evaluation of Bronchoalveolar Lavage Fluid from Patients in an Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - 10 States, August-October 2019. MMWR Morb Mortal Wkly Rep 2019; 68:1040.</a></li><li><a class="nounderline abstract_t">Heinzerling A, Armatas C, Karmarkar E, et al. Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019. JAMA Intern Med 2020; 180:861.</a></li><li><a class="nounderline abstract_t">Taylor J, Wiens T, Peterson J, et al. Characteristics of E-cigarette, or Vaping, Products Used by Patients with Associated Lung Injury and Products Seized by Law Enforcement - Minnesota, 2018 and 2019. MMWR Morb Mortal Wkly Rep 2019; 68:1096.</a></li><li><a class="nounderline abstract_t">Blount BC, Karwowski MP, Shields PG, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med 2020; 382:697.</a></li><li class="breakAll">Wu D, O'Shea D. Potential for release of pulmonary toxic ketene from vaping pyrolysis of vitamin E acetate. Chem Rxiv 2019. https://doi.org/10.26434/chemrxiv.10058168.v2 (Accessed on February 15, 2022).</li><li><a class="nounderline abstract_t">Bhat TA, Kalathil SG, Bogner PN, et al. An Animal Model of Inhaled Vitamin E Acetate and EVALI-like Lung Injury. N Engl J Med 2020; 382:1175.</a></li><li><a class="nounderline abstract_t">Maddock SD, Cirulis MM, Callahan SJ, et al. Pulmonary Lipid-Laden Macrophages and Vaping. N Engl J Med 2019; 381:1488.</a></li><li><a class="nounderline abstract_t">Blagev DP, Harris D, Dunn AC, et al. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet 2019; 394:2073.</a></li><li><a class="nounderline abstract_t">Kalininskiy A, Bach CT, Nacca NE, et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med 2019; 7:1017.</a></li><li><a class="nounderline abstract_t">Aberegg SK, Cirulis MM, Maddock SD, et al. Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use-Associated Lung Injury Among Patients Treated at an Academic Medical Center. JAMA Netw Open 2020; 3:e2019176.</a></li><li><a class="nounderline abstract_t">Reddy A, Jenssen BP, Chidambaram A, et al. Characterizing e-cigarette vaping-associated lung injury in the pediatric intensive care unit. Pediatr Pulmonol 2021; 56:162.</a></li><li><a class="nounderline abstract_t">Rao DR, Maple KL, Dettori A, et al. Clinical Features of E-cigarette, or Vaping, Product Use-Associated Lung Injury in Teenagers. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Matta P, Hamati JN, Unno HL, Fox MD. E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Without Respiratory Symptoms. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Khanijo S, Lou BX, Makaryus M, et al. Coagulopathy and Inflammatory Dysregulation with E-Cigarette Use. Am J Med 2020; 133:530.</a></li><li><a class="nounderline abstract_t">Kopsombut G, Ajjegowda A, Livingston F, et al. Clinical Findings in Adolescents Hospitalized With EVALI; Novel Report on Coagulopathy. Hosp Pediatr 2022; 12:229.</a></li><li><a class="nounderline abstract_t">Kligerman SJ, Kay FU, Raptis CA, et al. CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases. Chest 2021; 160:1492.</a></li><li><a class="nounderline abstract_t">Henry TS, Kanne JP, Kligerman SJ. Imaging of Vaping-Associated Lung Disease. N Engl J Med 2019; 381:1486.</a></li><li><a class="nounderline abstract_t">Henry TS, Kligerman SJ, Raptis CA, et al. Imaging Findings of Vaping-Associated Lung Injury. AJR Am J Roentgenol 2020; 214:498.</a></li><li><a class="nounderline abstract_t">Conuel EJ, Chieng HC, Fantauzzi J, et al. Cannabinoid Oil Vaping-Associated Lung Injury and its Radiographic Appearance. Am J Med 2020; 133:865.</a></li><li><a class="nounderline abstract_t">Wang KY, Jadhav SP, Yenduri NJS, et al. E-cigarette or vaping product use-associated lung injury in the pediatric population: imaging features at presentation and short-term follow-up. Pediatr Radiol 2020; 50:1231.</a></li><li><a class="nounderline abstract_t">Panse PM, Feller FF, Butt YM, et al. Radiologic and Pathologic Correlation in EVALI. AJR Am J Roentgenol 2020; 215:1057.</a></li><li><a class="nounderline abstract_t">Ashraf O, Nasrullah A, Karna R, Alhajhusain A. Vaping associated spontaneous pneumothorax - A case series of an enigmatic entity! Respir Med Case Rep 2021; 34:101535.</a></li><li><a class="nounderline abstract_t">Adhikari R, Manduva D, Malayala SV, et al. A Rare Case of Vaping-Induced Spontaneous Pneumomediastinum. Cureus 2021; 13:e17166.</a></li><li><a class="nounderline abstract_t">Thakrar PD, Boyd KP, Swanson CP, et al. E-cigarette, or vaping, product use-associated lung injury in adolescents: a review of imaging features. Pediatr Radiol 2020; 50:338.</a></li><li><a class="nounderline abstract_t">Larsen BT, Butt YM, Smith ML. More on the Pathology of Vaping-Associated Lung Injury. Reply. N Engl J Med 2020; 382:388.</a></li><li><a class="nounderline abstract_t">Aberegg SK, Maddock SD, Blagev DP, Callahan SJ. Diagnosis of EVALI: General Approach and the Role of Bronchoscopy. Chest 2020; 158:820.</a></li><li><a class="nounderline abstract_t">Ghosh A, Ahmad S, Coakley RD, et al. Lipid-laden Macrophages Are Not Unique to Patients with E-Cigarette or Vaping Product Use-associated Lung Injury. Am J Respir Crit Care Med 2021; 203:1030.</a></li><li><a class="nounderline abstract_t">Reagan-Steiner S, Gary J, Matkovic E, et al. Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series. Lancet Respir Med 2020; 8:1219.</a></li><li><a class="nounderline abstract_t">Mukhopadhyay S, Mehrad M, Dammert P, et al. Lung Biopsy Findings in Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping). Am J Clin Pathol 2020; 153:30.</a></li><li><a class="nounderline abstract_t">Marsden L, Michalicek ZD, Christensen ED. More on the Pathology of Vaping-Associated Lung Injury. N Engl J Med 2020; 382:387.</a></li><li><a class="nounderline abstract_t">Ring Madsen L, Vinther Krarup NH, Bergmann TK, et al. A Cancer That Went Up in Smoke: Pulmonary Reaction to e-Cigarettes Imitating Metastatic Cancer. Chest 2016; 149:e65.</a></li><li><a class="nounderline abstract_t">Mulligan KM, Zheng DX, Gallo Marin B, et al. COVID-19 and EVALI: Considerations regarding two concurrent public health crises. Am J Emerg Med 2022; 56:389.</a></li><li><a class="nounderline abstract_t">Callahan SJ, Harris D, Collingridge DS, et al. Diagnosing EVALI in the Time of COVID-19. Chest 2020; 158:2034.</a></li><li><a class="nounderline abstract_t">Khan MS, Khateeb F, Akhtar J, et al. Organizing pneumonia related to electronic cigarette use: A case report and review of literature. Clin Respir J 2018; 12:1295.</a></li><li><a class="nounderline abstract_t">Jankharia B, Rajan S, Angirish B. Vaping associated lung injury (EVALI) as an organizing pneumonia pattern- A case report. Lung India 2020; 37:533.</a></li><li><a class="nounderline abstract_t">Marchiori E, Zanetti G, Mano CM, et al. Lipoid pneumonia in 53 patients after aspiration of mineral oil: comparison of high-resolution computed tomography findings in adults and children. J Comput Assist Tomogr 2010; 34:9.</a></li><li><a class="nounderline abstract_t">Alzghoul BN, Innabi A, Mukhtar F, Jantz MA. Rapid Resolution of Severe Vaping-induced Acute Lipoid Pneumonia after Corticosteroid Treatment. Am J Respir Crit Care Med 2020; 202:e32.</a></li><li><a class="nounderline abstract_t">Betancourt SL, Martinez-Jimenez S, Rossi SE, et al. Lipoid pneumonia: spectrum of clinical and radiologic manifestations. AJR Am J Roentgenol 2010; 194:103.</a></li><li><a class="nounderline abstract_t">Edmonds PJ, Copeland C, Conger A, Richmond BW. Vaping-induced diffuse alveolar hemorrhage. Respir Med Case Rep 2020; 29:100996.</a></li><li><a class="nounderline abstract_t">Sommerfeld CG, Weiner DJ, Nowalk A, Larkin A. Hypersensitivity Pneumonitis and Acute Respiratory Distress Syndrome From E-Cigarette Use. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Atkins G, Drescher F. Acute Inhalational Lung Injury Related to the Use of Electronic Nicotine Delivery System (ENDS). Chest 2015; 148:83A.</a></li><li><a class="nounderline abstract_t">Nair N, Hurley M, Gates S, et al. Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes. Arch Dis Child 2020; 105:1114.</a></li><li><a class="nounderline abstract_t">Flower M, Nandakumar L, Singh M, et al. Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy. Respirol Case Rep 2017; 5:e00230.</a></li><li><a class="nounderline abstract_t">Adams TN, Butt YM, Batra K, Glazer CS. Cobalt related interstitial lung disease. Respir Med 2017; 129:91.</a></li><li><a class="nounderline abstract_t">Siegel DA, Jatlaoui TC, Koumans EH, et al. Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury - United States, October 2019. MMWR Morb Mortal Wkly Rep 2019; 68:919.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Board A, Calfee CS, et al. Pulmonary and Critical Care Considerations for e-Cigarette, or Vaping, Product Use-Associated Lung Injury. Chest 2022; 162:256.</a></li><li><a class="nounderline abstract_t">Mikosz CA, Danielson M, Anderson KN, et al. Characteristics of Patients Experiencing Rehospitalization or Death After Hospital Discharge in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 68:1183.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Lung injury: Outbreak of lung injury associated with e-cigarette use, or vaping. Available at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/healthcare-providers/index.html (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Carlos WG, Crotty Alexander LE, Gross JE, et al. Vaping-associated Pulmonary Illness (VAPI). Am J Respir Crit Care Med 2019; 200:P13.</a></li><li class="breakAll">US Food and Drug Administration. Lung injuries associated with use of vaping products. https://www.fda.gov/news-events/public-health-focus/lung-injuries-associated-use-vaping-products?Connect=&amp;SOS%3A_Vaping_Illness_-_91219= (Accessed on December 15, 2021).</li><li><a class="nounderline abstract_t">Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and Deaths Associated with EVALI. N Engl J Med 2020; 382:1589.</a></li><li><a class="nounderline abstract_t">Corcoran A, Carl JC, Rezaee F. The importance of anti-vaping vigilance-EVALI in seven adolescent pediatric patients in Northeast Ohio. Pediatr Pulmonol 2020; 55:1719.</a></li><li><a class="nounderline abstract_t">Carroll BJ, Kim M, Hemyari A, et al. Impaired lung function following e-cigarette or vaping product use associated lung injury in the first cohort of hospitalized adolescents. Pediatr Pulmonol 2020; 55:1712.</a></li><li><a class="nounderline abstract_t">Blagev DP, Callahan SJ, Harris D, et al. Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette- or Vaping-associated Lung Injury. Ann Am Thorac Soc 2022; 19:1892.</a></li></ol></div><div id="topicVersionRevision">Topic 122671 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570493" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : What are the respiratory effects of e-cigarettes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31574235" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vaping-associated Acute Lung Injury: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31491072" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990264" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990264" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990264" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36584985" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The E-cigarette or Vaping Product Use-Associated Lung Injury Epidemic: Pathogenesis, Management, and Future Directions: An Official American Thoracic Society Workshop Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513561" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe Pulmonary Disease Associated with Electronic-Cigarette-Product Use - Interim Guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31539466" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Real-Time Digital Surveillance of Vaping-Induced Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751326" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vaping-Related Acute Parenchymal Lung Injury: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860794" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Syndromic Surveillance for E-Cigarette, or Vaping, Product Use-Associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806720" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An imported case of e-cigarette or vaping associated lung injury in Barcelona.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32265304" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diffuse alveolar haemorrhage secondary to e-cigarette "vaping" associated lung injury (EVALI) in a young European consumer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217651" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fatal e-cigarette or vaping associated lung injury (EVALI): a first case report in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577870" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathology of Vaping-Associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462024" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29984031" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diffuse Alveolar Hemorrhage Induced by Vaping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982176" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Respiratory failure caused by lipoid pneumonia from vaping e-cigarettes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474155" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An unexpected consequence of electronic cigarette use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513559" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia - North Carolina, July-August 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31491071" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vaping-Induced Acute Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31581168" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31581166" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury - Illinois and Wisconsin, April-September 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725707" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of Bronchoalveolar Lavage Fluid from Patients in an Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - 10 States, August-October 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32142111" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774740" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characteristics of E-cigarette, or Vaping, Products Used by Patients with Associated Lung Injury and Products Seized by Law Enforcement - Minnesota, 2018 and 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860793" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860793" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101656" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An Animal Model of Inhaled Vitamin E Acetate and EVALI-like Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31491073" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary Lipid-Laden Macrophages and Vaping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711629" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711871" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33156346" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use-Associated Lung Injury Among Patients Treated at an Academic Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970368" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Characterizing e-cigarette vaping-associated lung injury in the pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32393606" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical Features of E-cigarette, or Vaping, Product Use-Associated Lung Injury in Teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317307" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Without Respiratory Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31821789" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Coagulopathy and Inflammatory Dysregulation with E-Cigarette Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35098298" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical Findings in Adolescents Hospitalized With EVALI; Novel Report on Coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33957099" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31491070" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Imaging of Vaping-Associated Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593518" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Imaging Findings of Vaping-Associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751528" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cannabinoid Oil Vaping-Associated Lung Injury and its Radiographic Appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32495177" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : E-cigarette or vaping product use-associated lung injury in the pediatric population: imaging features at presentation and short-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877245" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Radiologic and Pathologic Correlation in EVALI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34745871" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vaping associated spontaneous pneumothorax - A case series of an enigmatic entity!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34532191" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Rare Case of Vaping-Induced Spontaneous Pneumomediastinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31897566" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : E-cigarette, or vaping, product use-associated lung injury in adolescents: a review of imaging features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31747508" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : More on the Pathology of Vaping-Associated Lung Injury. Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32092322" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis of EVALI: General Approach and the Role of Bronchoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332247" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lipid-laden Macrophages Are Not Unique to Patients with E-Cigarette or Vaping Product Use-associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763198" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31621873" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lung Biopsy Findings in Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31747506" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : More on the Pathology of Vaping-Associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965975" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Cancer That Went Up in Smoke: Pulmonary Reaction to e-Cigarettes Imitating Metastatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34893400" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : COVID-19 and EVALI: Considerations regarding two concurrent public health crises.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32599069" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnosing EVALI in the Time of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29392888" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Organizing pneumonia related to electronic cigarette use: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33154217" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vaping associated lung injury (EVALI) as an organizing pneumonia pattern- A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118714" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lipoid pneumonia in 53 patients after aspiration of mineral oil: comparison of high-resolution computed tomography findings in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32142357" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rapid Resolution of Severe Vaping-induced Acute Lipoid Pneumonia after Corticosteroid Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028911" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lipoid pneumonia: spectrum of clinical and radiologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31956478" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vaping-induced diffuse alveolar hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773665" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hypersensitivity Pneumonitis and Acute Respiratory Distress Syndrome From E-Cigarette Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acute Inhalational Lung Injury Related to the Use of Electronic Nicotine Delivery System (ENDS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712273" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28392919" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28732841" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cobalt related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31633675" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury - United States, October 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35257738" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pulmonary and Critical Care Considerations for e-Cigarette, or Vaping, Product Use-Associated Lung Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895917" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Characteristics of Patients Experiencing Rehospitalization or Death After Hospital Discharge in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895917" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Characteristics of Patients Experiencing Rehospitalization or Death After Hospital Discharge in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532695" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Vaping-associated Pulmonary Illness (VAPI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532695" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Vaping-associated Pulmonary Illness (VAPI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320569" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hospitalizations and Deaths Associated with EVALI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32462762" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The importance of anti-vaping vigilance-EVALI in seven adolescent pediatric patients in Northeast Ohio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320538" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Impaired lung function following e-cigarette or vaping product use associated lung injury in the first cohort of hospitalized adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35533314" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette- or Vaping-associated Lung Injury.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
